Welcome to our dedicated page for Emergent Biosolutions SEC filings (Ticker: EBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Emergent BioSolutions Inc. (NYSE: EBS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a New York Stock Exchange‑listed pharmaceutical preparation manufacturing company, Emergent submits annual reports on Form 10‑K, quarterly reports on Form 10‑Q and current reports on Form 8‑K that describe its operations, financial condition and material events.
In its recent Form 8‑K filings, Emergent has reported topics such as quarterly financial and operating results, voluntary prepayment under a term loan facility, contract modifications and options for medical countermeasures, regulatory approvals for manufacturing changes, and changes in board membership. These current reports often incorporate press releases and presentation materials by reference, giving additional detail on product revenues, segment performance and government contract activity.
Filings also confirm that Emergent’s common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol EBS. Disclosures identify its reportable segments, including Commercial Products and MCM Products, and describe how Services and contracts and grants revenues are presented. Other events filings outline contract modifications with agencies such as the Administration for Strategic Preparedness and Response and BARDA for products including ACAM2000®, CYFENDUS™, BioThrax® and BAT®.
On Stock Titan, investors can review these SEC documents alongside AI‑generated summaries that highlight key points from lengthy filings. Real‑time updates from EDGAR surface new 10‑K and 10‑Q reports as they are filed, while Form 8‑K items flag significant developments in financing, contracts, regulatory approvals and governance. Users can also track how Emergent describes its medical countermeasures portfolio, naloxone products and segment structure over time through its official regulatory language.
Emergent BioSolutions Inc. executive vice president and chief financial officer Richard S. Lindahl reported the expiration of two employee stock option awards. Stock options for 20,321 shares and 19,963 shares expired unexercised pursuant to their terms, and the footnotes state that no value was received upon expiration.
Emergent BioSolutions Inc. reported that President and CEO Joseph C. Papa received an award of employee stock options covering 252,194 shares on March 3, 2026, at an exercise price of $0.00 per share. These options vest in three equal installments beginning the day prior to each anniversary of the grant date.
On March 5, 2026, 37,055 shares of common stock were withheld and disposed of to cover taxes tied to the vesting and settlement of performance stock units at a price of $8.44 per share, leaving Papa with 305,445 common shares directly owned.
FOWLER JOHN D JR reported acquisition or exercise transactions in this Form 4 filing.
Emergent BioSolutions Inc. director John D. Fowler Jr reported an equity award of 5,006 shares of common stock in the form of restricted stock units. The units were granted at a reference value of $8.99 per share and were issued under the company’s Stock Incentive Plan.
These 5,006 restricted stock units vest in three annual installments, beginning on the day prior to the anniversary of the grant date, assuming he continues serving the company. Each unit represents the right to receive one share of Emergent BioSolutions common stock, and Fowler now directly holds 5,006 shares following this grant.
Emergent BioSolutions Inc. director John D. Fowler Jr filed an initial ownership report on Form 3 showing he directly beneficially owns no shares of the company’s common stock as of the reported date. The filing does not report any buy or sell transactions, only a zero balance.
Emergent BioSolutions SVP, R&D, CMO Simon C. Lowry reported two equity compensation transactions. On March 5, 2026, 10,636 shares of common stock were disposed of at
Emergent BioSolutions senior vice president William Hartzel reported routine equity compensation transactions. On March 5, 2026, 9,493 shares of common stock were disposed of at $8.44 per share to cover taxes tied to restricted stock unit vesting, leaving him with 87,188 shares of common stock held directly.
On March 3, 2026, he received a grant of 44,834 employee stock options, increasing his directly held options to 259,545. The grant is scheduled to vest in three equal installments beginning on the day prior to each anniversary of the grant date.
Emergent BioSolutions Inc. reported insider equity activity by SVP and General Counsel Jessica Perl. She received a grant of 46,702 employee stock options at an exercise price of $0.00 per option on common stock. According to a footnote, these options vest in three equal installments beginning on the day prior to the anniversary date of the grant.
On a separate date, 6,465 shares of common stock were disposed of in a tax-withholding disposition at $8.44 per share, with a footnote explaining the shares were withheld to pay taxes associated with the vesting and settlement of restricted stock units. Following these transactions, Perl directly owned 61,004 common shares and held 142,647 stock options.
Emergent BioSolutions Inc. senior vice president Paul Anthony Williams reported two equity compensation transactions. On March 5, 2026, 9,397 shares of common stock were disposed of at
On March 3, 2026, he received a grant of employee stock options for 44,834 shares at an exercise price of
Emergent BioSolutions EVP and CFO Richard S. Lindahl reported routine equity compensation and related tax withholding. On March 3, he acquired 72,856 employee stock options at an exercise price of $0.00 per share as a grant that vests in three equal installments beginning the day prior to each anniversary of the grant date. On March 5, 23,650 shares of common stock were disposed of at $8.44 per share to cover taxes due on the vesting and settlement of restricted stock units, rather than through an open-market sale. After these transactions, he held 215,367 shares of common stock and 557,346 stock options directly.
Emergent BioSolutions EVP Coleen Glessner reported a stock option grant and a related tax-withholding share disposition. On March 3, she acquired 44,834 Employee Stock Options (right to buy common stock) as a grant with a stated price of $0.00 per option, which vest in three equal installments beginning on the day prior to each anniversary of the grant date.
On March 5, 8,199 shares of common stock were withheld and disposed of to cover taxes associated with the vesting and settlement of restricted stock units. After these transactions, she directly owned 104,108 shares of common stock and 294,447 stock options.